Search Results - "Wiendl, H."

The impact of lesion location on dysphagia incidence, pattern and complications in acute stroke. Part 1: dysphagia incidence, severity and aspiration by Suntrup, S., Kemmling, A., Warnecke, T., Hamacher, C., Oelenberg, S., Niederstadt, T., Heindel, W., Wiendl, H., Dziewas, R.

“…Background and purpose Although early identification of patients at risk for dysphagia is crucial in acute stroke care, predicting whether a particular patient…”
Get full text

The impact of lesion location on dysphagia incidence, pattern and complications in acute stroke. Part 2: Oropharyngeal residue, swallow and cough response, and pneumonia by Suntrup‐Krueger, S., Kemmling, A., Warnecke, T., Hamacher, C., Oelenberg, S., Niederstadt, T., Heindel, W., Wiendl, H., Dziewas, R.

“…Background and purpose Dysphagia is a well‐known complication of acute stroke. Given the complexity of cerebral swallowing control it is still difficult to…”
Get full text

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., Pilling, S., Selmaj, K., Siva, A., Sorensen, P. S., Sormani, M. P., Thalheim, C., Wiendl, H., Zipp, F.

“…Background and purpose Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is therefore a need for a…”
Get full text

Exercise facilitates post-stroke recovery through mitigation of neuronal hyperexcitability via interleukin-10 signaling by Schmidt-Pogoda, A., Ruck, T., Strecker, JK, Hoppen, M., Fazio, L., Vinnenberg, L., Maus, B., Wachsmuth, L., Cerina, M., Diederich, K., Lichtenberg, S., Abberger, H., Haertel, LAL, Schafflick, D., Meyer zu Hörste, G., Herrmann, AM, Hundehege, P., Narayanan, V., Nelke, C., Kruithoff, K., Bosbach, J., Vicari, E., Ramcke, T., Beuker, C., Hadaschik, E., Budde, T., Faber, C., Wiendl, H., Hansen, W., Meuth, SG, Minnerup, J.

“…Physical exercise is an effective therapy for improving stroke recovery. However, the exact underlying molecular mechanisms of exercise-enhanced neuronal…”
Get full text

Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series by Dogan Onugoren, M, Deuretzbacher, D, Haensch, C A, Hagedorn, H J, Halve, S, Isenmann, S, Kramme, C, Lohner, H, Melzer, N, Monotti, R, Presslauer, S, Schäbitz, W R, Steffanoni, S, Stoeck, K, Strittmatter, M, Stögbauer, F, Trinka, E, von Oertzen, T J, Wiendl, H, Woermann, F G, Bien, C G

“…BackgroundTwo novel antibodies (abs) directed to γ-aminobutyric acid B receptor (GABABR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor…”
Get full text

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort by Trampe, A K, Hemmelmann, C, Stroet, A, Haghikia, A, Hellwig, K, Wiendl, H, Goelz, S, Ziegler, A, Gold, R, Chan, A

“…To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the…”
Get more information

CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy by Schneider-Hohendorf, T, Schwab, N, Uçeyler, N, Göbel, K, Sommer, C, Wiendl, H

“…Chronic inflammatory demyelinating polyradiculopathy (CIDP) is a common, but often misdiagnosed disease of the peripheral nervous system with assumed…”
Get more information

Increased frequency of CD4⁺ CD25⁺ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients by Feger, U, Luther, C, Poeschel, S, Melms, A, Tolosa, E, Wiendl, H

“…Naturally occurring CD4⁺ CD25⁺ regulatory T cells (nTreg) play a major role in controlling autoimmunity by suppressing self-reactive T cells. Multiple…”
Get full text

Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis by Johnen, A., Elpers, C., Riepl, E., Landmeyer, N.C., Krämer, J., Polzer, P., Lohmann, H., Omran, H., Wiendl, H., Göbel, K., Meuth, S.G.

“…Cognitive impairment (CI) is a critical feature for patients with childhood or juvenile multiple sclerosis (MS). To promote the understanding of CI and to…”
Get full text

P 24. Dysphagia in NMOSD and MOGAD: Swallowing endoscopy as a surrogate of brain involvement? by Pawlitzki, M., Ahring, S., Rolfes, L., Dziewas, R., Warnecke, T., Suntrup-Krueger, S., Wiendl, H., Klotz, L., Meuth, S.G., Labeit, B.

“…Background. Neuromyelitis optica spectrum disorder (NMOSD) and Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) are demyelinating disorders…”
Get full text

P 42. ALS patients show increased T-cell activation in peripheral blood and cerebrospinal fluid by Pawlitzki, M., Schulte-Mecklenbeck, A., Schreiber, S., Vielhaber, S., Herty, M., Marten, A., Pfeuffer, S., Ruck, T., Wiendl, H., Gross, C.C., Meuth, S.G., Boentert, M., Rolfes, L.

“…Objective. We investigated intrathecal and peripheral immune profiles in amyotrophic lateral sclerosis (ALS) patients compared to controls free of neurological…”
Get full text

Therapeutic Approaches in Multiple Sclerosis: Lessons from Failed and Interrupted Treatment Trials by Wiendl, Heinz, Hohlfeld, Reinhard

“…The therapy for multiple sclerosis (MS) has changed dramatically over the past decade. Recent immunobiological findings and current pathophysiological concepts…”
Get full text

Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children by Lalive, PH, Häusler, MG, Maurey, H, Mikaeloff, Y, Tardieu, M, Wiendl, H, Schroeter, M, Hartung, HP, Kieseier, BC, Menge, T

“…Background: Myelin oligodendrocyte glycoprotein (MOG) may be implicated in the immunopathogenesis of multiple sclerosis (MS) inducing demyelination in the…”
Get full text

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control by Schwab, N, Ulzheimer, J C, Fox, R J, Schneider-Hohendorf, T, Kieseier, B C, Monoranu, C M, Staugaitis, S M, Welch, W, Jilek, S, Du Pasquier, R A, Brück, W, Toyka, K V, Ransohoff, R M, Wiendl, H

“…Progressive multifocal leukoencephalopathy (PML) has become much more common with monoclonal antibody treatment for multiple sclerosis and other…”
Get more information

Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke by Schulte‐Mecklenbeck, A., Kleffner, I., Beuker, C., Wirth, T., Hartwig, M., Schmidt‐Pogoda, A., Klotz, L., Hansen, W., Wiendl, H., Meuth, S. G., Gross, C. C., Minnerup, J.

“…Background and purpose Post‐ischaemic immune cell invasion into the brain is well characterized in animal stroke models and contributes to neuronal damage…”
Get full text

Myositiden: Pathogenese und Therapie by Wiendl, H.

Get full text

Long-term effects of dalfampridine in patients with multiple sclerosis by Ruck, T., Bittner, S., Simon, O.J., Göbel, K., Wiendl, H., Schilling, M., Meuth, S.G.

“…Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with…”
Get full text

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy by Harrer, A, Tumani, H, Niendorf, S, Lauda, F, Geis, C, Weishaupt, A, Kleinschnitz, C, Rauer, S, Kuhle, J, Stangel, M, Weber, F, Uhr, M, Linnebank, M, Wildemann, B, Jarius, S, Guger, M, Ayzenberg, I, Chan, A, Zettl, U, Wiendl, H, Pilz, G, Hitzl, W, Weber, JR, Kraus, J

“…Recently, the disappearance of oligoclonal bands (OCBs) from the cerebrospinal fluid (CSF) of a few natalizumab-treated patients with multiple sclerosis (MS)…”
Get full text

Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results) by Vermersch, P., Eralinna, J.P., Nicholas, R., Oreja-Guevara, C., Siva, A., Van Wijmeersch, B., Wiendl, H., Buffels, R., Kuhelj, R., Wei, W., Comi, G.

Get full text

21245. EFGARTIGIMOD PH20 SUBCUTÁNEO (SC) EN PACIENTES CON MIASTENIA GRAVIS GENERALIZADA (MGG) EN ADAPTSC+: ANÁLISIS INTERMEDIO DE CALIDAD DE VIDA (QOL), EFICACIA, TOLERABILIDAD Y SEGURIDAD A LARGO PLAZO by Sivera Mascaró, R., Vu, T., F Howard, J., Korobko, D., Smilowski, M., Gistelinck, F., Steeland, S., Noukens, J., Podhorna, J., Li, Y., Utsugisawa, K., Saccà, F., Wiendl, H., L De Beecker, J., Mantegazza, R.

Get full text